Teva Pharma Industries Ltd ADR (TEVA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $51.92B
Last updated: Nov 17, 2026 at 11:06 AM ET
Teva Pharma Industries Ltd ADR (TEVA) Stock Forecast
Analysts expect Teva Pharma Industries Ltd ADR (TEVA) to earn $2.06 per share in the fiscal year ending Dec 31, 2026, on revenue of $16.78B. Of 13 analysts, 12 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.77, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 30.8% |
| Buy | 8 | 61.5% |
| Hold | 1 | 7.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 51.9% and revenue estimates rise 3.4%.
- Fiscal year ending Dec 31, 2026
- $2.06
- EPS consensus, revenue $16.78B
- Fiscal year ending Dec 31, 2027
- $3.13
- EPS consensus, revenue $17.35B
- Fiscal year ending Dec 31, 2028
- $3.44
- EPS consensus, revenue $17.99B
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.06 | $1.98 to $2.30 | 14 | $16.78B | $16.68B to $16.87B | 11 |
| Dec 31, 2027 | $3.13 | $2.83 to $3.50 | 15 | $17.35B | $16.78B to $17.69B | 13 |
| Dec 31, 2028 | $3.44 | $3.12 to $3.80 | 3 | $17.99B | $17.98B to $18.00B | 8 |
Quarterly Estimates
The EPS consensus falls from $0.68 for the quarter ending Dec 31, 2026 to $0.61 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.68 | $0.60 to $0.81 | 5 | $4.34B | $4.11B to $4.53B | 5 |
| Mar 31, 2027 | $0.61 | $0.42 to $0.69 | 9 | $4.07B | $4.00B to $4.13B | 7 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
EPS Trend
Over the last 30 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 2.4% from $2.11.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.06 | $2.07 | $2.11 | N/A | N/A | N/A |
| Fiscal year ending Dec 31, 2027 | $3.13 | $3.13 | $3.08 | N/A | N/A | N/A |
| Quarter ending Mar 31, 2027 | $0.61 | $0.63 | $0.63 | N/A | N/A | N/A |
Frequently Asked Questions About TEVA
What is the TEVA stock forecast?
Consensus analyst estimates put Teva Pharma Industries Ltd ADR's EPS at $2.06 for the fiscal year ending Dec 31, 2026, on revenue of $16.78B. The consensus rating from 13 analysts is Buy.
How do analysts rate TEVA stock?
Of 13 analysts covering Teva Pharma Industries Ltd ADR, 4 rate it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TEVA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.06, with estimates from $1.98 to $2.30 from 14 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.13, with estimates from $2.83 to $3.50 from 15 analysts.
What revenue do analysts expect from Teva Pharma Industries Ltd ADR next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $16.78B, with estimates from $16.68B to $16.87B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $17.35B, with estimates from $16.78B to $17.69B.
How many analysts cover TEVA?
13 analysts rate Teva Pharma Industries Ltd ADR stock, and 14 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TEVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors